What Chitolytic does

ChitoLytic is a Toronto-based chitosan manufacturer and supplier, established in 2011 as a spin-off from ChitOcean, that produces high-purity chitosan and chitosan derivatives for R&D and commercial buyers across biomedical, pharmaceutical, food/nutraceutical, cosmetics, agriculture, and industrial end-markets. The company's underlying technology is a proprietary clean-tech enzymatic process for demineralization and deproteinization of crustacean shells (shrimp and snow crab), co-developed with Memorial University's Marine Institute, which replaces the harsh chemical inputs of conventional methods and produces near chemical-free effluent. A second proprietary technology — non-thermal plasma treatment — is used to manufacture ultra-pure, endotoxin-free (<1.0 EU/g), terminally sterile chitosan suitable for parenteral injection and implantation, complemented by benchtop NMR-based quality control developed in partnership with Nanalysis. Products span crustacean and mushroom (Agaricus bisporus) sources across a tunable range of degrees of deacetylation (80%–>98%) and molecular weights (<3 kDa to 400–800 kDa), with derivatives including oligosaccharides, chitosan lactate, and trimethyl chitosan.

ChitoLytic monetizes almost exclusively through one-time unit-priced sales of chitosan products, with prices ranging from roughly $15–$135/kg for industrial-grade chitin to $34.14/g ($34,140/kg) for ultra-clean endotoxin-free chitosan and up to $100/g for trimethyl chitosan, with volume discounts available on larger orders and minimum order quantities as low as 1–5 grams for specialty SKUs. The company operates a sales-led and inside-sales GTM with toll-free North American and international phone lines, project consultation services, and a direct e-commerce storefront at chitolytic.com, supported by listing on ThomasNet and Knowde industrial/chemical marketplaces for procurement-led discovery. Customer segments are horizontal: biomedical and pharmaceutical use cases (tissue engineering, drug delivery, woundcare, medical devices) are the primary target, with secondary segments in cosmetics, food/nutraceutical, agriculture (including IR4-tested biopesticide applications), and industrial uses (water treatment, textiles, biodegradable films). Products are certified under GMP, ISO 9001, and NSF standards, and the company offers collaboration, licensing, joint venture, and project-funding engagements for selected chitosan-included projects, with a ChitoLytic Diagnostics sub-brand addressing diagnostic applications as a separate go-to-market.

Name

Chitolytic

Legal name

ChitoLytic

Website

https://chitolytic.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Toronto-based chitosan manufacturer and supplier offering crustacean- and mushroom-derived grades and derivatives for biomedical, pharmaceutical, food, agricultural, and industrial buyers, using proprietary enzymatic and plasma-treatment processes and selling globally via direct e-commerce and B2B marketplaces.

Ownership category

akta.pro rank

Product category

Chitosan Manufacturing

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Hydrocolloids, Thickeners & Gelling Agents (Pectin, Xanthan, Carrageenan, Gelatin) (CRADAOAD)

Keywords

• Chitosan manufacturing
• Pharmaceutical excipients
• Biopolymer materials
• Medical grade chitosan
• Specialty chemical supply

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Chitosan Product Sales: Direct sales of chitosan products including various grades, molecular weights, and derivatives. Products are sold in standard quantities (100g, 250g, 500g, 1kg+) with pricing per gram or kilogram. Volume discounts available for larger orders.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

ChitoLytic manufactures and supplies pure, high-quality chitosan products derived from crustacean shells (shrimp, snow crab) and mushroom (Agaricus bisporus) sources for R&D and commercial applications. The company offers standard grades, specialty derivatives (oligosaccharides, lactate, trimethyl chitosan), and ultra-pure endotoxin-free grades for biomedical, pharmaceutical, food, agricultural, and industrial sectors. They also provide customized chitosan formulation services and support customers in qualifying chitosan for medical/pharmaceutical-grade use.

Product overview

ChitoLytic is a specialized chitosan supplier and manufacturer operating in North America (USA and Canada) that ships worldwide. The company offers pure, high-quality chitosan products categorized into three main product lines: (1) Crustacean-Sourced Chitosans derived from shrimp and snow crab shells, including various grades differentiated by degree of deacetylation (DDA%) and molecular weight; (2) Mushroom (Plant-Based/Vegetal) Chitosans derived from Agaricus bisporus for non-animal applications; and (3) Specialty Chitosan Derivatives including oligosaccharides (mushroom and crustacean sources), chitosan lactate, and trimethyl chitosan. Additional offerings include chitin supply (raw material), customized chitosan products, and services to achieve medical/pharmaceutical-grade chitosan. Products are certified under GMP and ISO 9001 standards, with some grades featuring plasma-treatment for endotoxin-free applications.

Differentiator

Problem solved

Functional benefit

Brands

• ChitoLytic Diagnostics: Referenced as a specialized division at chitolyticdiagnostics.com, suggesting a separate branded entity for diagnostic applications of chitosan technology.

Products and services

• Pure Ultra-Clean Chitosan Depyrogenated, terminally sterile, endotoxin-free chitosan (cc-PUC) processed through plasma-treatment to achieve validated purity with endotoxin specification below 10.0 EU/g. Designed for implantation and parenteral injection applications in biomedical and pharmaceutical R&D.
• Crustacean Chitosan – Very High DDA, Low Molecular Weight Crustacean-sourced chitosan (Snow Crab) with 95.6% deacetylation and 66 cps viscosity. Suitable for scaffolds, cell therapy, drug delivery, and biomedical applications including wound-healing and tissue engineering.
• Low Molecular Weight Chitosan (B-90-471692) High deacetylation (91.5%) chitosan with 75 cps viscosity derived from crustacean shells. Designed for pharmaceutical, medical, food, personal care, and agricultural applications requiring enhanced solubility and bioadhesion.
• Low Molecular Weight Chitosan (A-90101) High-purity, low molecular weight chitosan (50-190 kDa) with 90.1% deacetylation. Features superior solubility, low viscosity, and tunable bioactivity for hydrogels, films, injectable, sprayable, or nanoparticle systems.
• Mushroom Chitosan Low to Medium Molecular Weight Plant-based, non-animal chitosan derived from Agaricus bisporus mushrooms. High deacetylation (85-90%) with low to medium molecular weight. Biocompatible, biodegradable, and antibacterial for tissue engineering and drug delivery applications where animal-derived materials are unsuitable.
• Mushroom Chitosan Very High DDA Vegetal, non-animal chitosan from Agaricus bisporus with over 95% deacetylation and 250-300 kDa molecular weight. Forms gels with multivalent anions and clear solutions for biomedical applications.
• Chitosan Oligosaccharide (Mushroom) Water-soluble oligomer derived from mushroom chitosan with 98.2% deacetylation and less than 3 kDa molecular weight. Exhibits anti-tumor, anti-inflammatory, antioxidant, and immune-enhancing properties for drugs, medical devices, food, cosmetics, and agriculture.
• Chitosan Oligosaccharide (Crustacean) Water-soluble chitosan oligosaccharide from Snow Crab shell with 86.5% deacetylation and very low molecular weight. Used for applications requiring high solubility and biological activity.
• Chitosan Lactate Water-soluble chitosan salt combining lactic acid onto amino groups. Over 70% deacetylation with superior solubility compared to standard chitosan. Used in biomedical and biochemical applications.
• Trimethyl Chitosan

Quantifiable outcome

• Endotoxin levels <1.0 EU/g for ultra-pure products through plasma treatment
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Memorial University - Marine Institute's Center of Aquaculture and Seafood DevelopmentcoreStrategic or Co-development PartnerChitoLytic's manufacturing technology originated from ChitOcean (founded 2011), which developed clean-tech chitosan manufacturing technology in collaboration with Memorial University's Marine Institute. The technology development partnership established the enzymatic process for demineralization and deproteinization of crustacean shells. This is a foundational technology partnership that enabled the company's proprietary manufacturing capabilities.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• FMC Corporation: Diversified specialty chemical and agricultural science major with biopolymer and chitosan-adjacent product lines in crop protection and food ingredients; a much larger incumbent competing for the agricultural and food-grade applications ChitoLytic serves.
• Cargill, Incorporated: Global agribusiness and food ingredient conglomerate with chitosan and chitin-derived ingredient offerings across food, nutraceutical, and animal feed applications; competes for the food-grade and nutraceutical end of ChitoLytic's customer base.
• TCI Chemicals: Global chemical catalog supplier offering chitosan, chitosan oligosaccharides, and derivatives at research and bulk quantities; competes with ChitoLytic on R&D-grade procurement and has far broader catalog and geographic reach.
• Sigma-Aldrich (Merck KGaA): World's largest life science and specialty chemical supplier with chitosan catalog products across multiple grades; the default incumbent customers procure from when ChitoLytic is not specified, putting downward pressure on volume share.

Direct peers

• Primex EHF: Iceland-based world leader in chitosan and chitin production from North Atlantic shrimp shells; most direct competitor with comparable crustacean-sourced GMP-grade chitosan portfolio targeting food, pharma, and biomedical applications.
• Glentham Life Sciences: UK-based chemical supplier offering chitosan and chitosan derivatives across research and industrial grades; competes directly with ChitoLytic in academic and R&D procurement channels.
• Heppe Medical Chitosan GmbH: German chitosan specialist focused exclusively on medical and pharmaceutical-grade chitosan with extensive derivative portfolio (oligosaccharides, lactate, trimethyl) — competes head-on with ChitoLytic's biomedical positioning.
• Alfa Chemistry: US-based chemical supplier and contract manufacturer with a chitosan product portfolio spanning research, food, and industrial grades; comparable in scale and breadth of offering to ChitoLytic.

Regional players

• China-based chitosan manufacturers (e.g., Golden-Shell, Aoxing Bio): Multiple Chinese chitosan producers supply commodity and specialty grades at lower cost to global markets including North America; they compete primarily on price in industrial and food applications where ChitoLytic's clean-tech and ultra-pure positioning differentiates the offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/chitolytic

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chitolytic